Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Dinitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | BCHE | P06276 | 6/20 | 0.64 |
| ▸ | GSR | P00390 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Dinitrate SCHEMBL19528695 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL9439417 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL1553054 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL8253 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL309369 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL3008938 | 0.98 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL714959 | 0.98 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL27976716 | 0.96 | ALDH1A1 (0.91) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL28209664 | 0.96 | ALDH1A1 (0.91) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL3864281 | 0.94 | ALDH1A1 (0.88) | ALDH1A1MAPTBCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3338813-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-3558399-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-01-14 | — | — | EP | claimed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | claimed |
| EP-3673259-B1 | POULTRY FEED AND POULTRY FEED ADDITIVE FOR USE IN REDUCING THE INCIDENCE OF PECTORAL MYOPATHY | CAN TECH INC (US) | 2024-12-18 | — | — | EP | claimed |
| EP-3357945-B1 | ADHESIVE POLYMER AND MEDICAL ADHESIVE PATCH | TEIKOKU SEIYAKU KK (JP) | 2024-10-30 | — | — | EP | claimed |
| EP-3890765-B1 | D-ARG-2'6'-DMT-LYS-PHE-NH2 FOR USE IN TREATING OR PREVENTING SENGERS SYNDROME | STEALTH BIOTHERAPEUTICS INC (US) | 2023-09-20 | — | — | EP | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-3599243-B1 | 17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE | CVIE THERAPEUTICS LTD (TW) | 2023-04-12 | — | — | EP | claimed |
| EP-3842076-B1 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2023-02-15 | — | — | EP | claimed |
| EP-3195168-B1 | A METHOD FOR THE IDENTIFICATION OF IMMUNOTHERAPY-DRUG COMBINATIONS USING A NETWORK APPROACH | UNIV WESTERN AUSTRALIA (AU) | 2022-09-07 | — | — | EP | claimed |
| EP-3297587-B1 | INTRAVENOUS ACCESS DEVICE | GATEWAY DEVICES LTD (GB) | 2022-03-23 | — | — | EP | claimed |
| EP-1506193-B9 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-1506193-B3 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2025-12-03 | — | — | EP | disclosed |
| EP-4599827-A1 | DGL FOR THE INDUCTION OF ENDOTHELIAL-DERIVED NO-DEPENDENT VASODILATION | Dr. Kurt Wolff GmbH & Co. KG (DE) | 2025-08-13 | — | — | EP | disclosed |
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-3826627-B1 | ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORM WITH MODIFIED RELEASE | BAYER AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| EP-3325013-B2 | STIMULATORS / ACTIVATORS OF SOLUBLE GUANYLAT CYCLASE IN COMBINATION WITH A NEP-INHIBITOR AND AN ANGIOTENSIN AII-ANTAGONIST AND THE USE THEREOF | Bayer Pharma AG (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-2938328-B1 | MONOLITHIC PHARMACEUTICAL FORM FOR MODIFIED RELEASE OF AN ACTIVE INGREDIENT COMBINATION | HENNIG ARZNEIMITTEL GMBH&CO KG (DE) | 2023-07-05 | — | — | EP | disclosed |